RNA-Seq and Immune Repertoire Analysis of Normal and Hepatocellular Carcinoma Relapse After Liver Transplantation

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/s0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–548. doi:10.1001/jamaoncol.2016.5688
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–217. doi:10.1038/nrgastro.2016.193
   PubMed Web of Science ®Google Scholar
• Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection? Liver Transpl. 2017;23(4):440–447. doi:10.1002/lt.24742
   PubMed Web of Science ®Google Scholar
• Kim M, Rhu J, Choi GS, et al. Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation. Ann Surg Treat Res. 2021;101(1):28–36. doi:10.4174/astr.2021.101.1.28
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/nejm199603143341104
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–1403. doi:10.1053/jhep.2001.24563
   PubMed Web of Science ®Google Scholar
• Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol. 2012;6(4):445–457. doi:10.1016/j.molonc.2012.04.001
   PubMed Web of Science ®Google Scholar
• Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98(1):119–127. doi:10.1002/cncr.11487
   PubMed Web of Science ®Google Scholar
• Sieghart W, Wang X, Schmid K, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol. 2011;54(1):89–97. doi:10.1016/j.jhep.2010.06.030
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361(9361):923–929. doi:10.1016/s0140-6736(03)12775-4
   PubMed Web of Science ®Google Scholar
• Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004;41(2):284–291. doi:10.1016/j.jhep.2004.04.031
   PubMed Web of Science ®Google Scholar
• Xue F, Higgs BW, Huang J, et al. HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med. 2015;13(379). doi:10.1186/s12967-015-0743-2
   Google Scholar
• Chan EY, Larson AM, Fix OK, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl. 2008;14(7):956–965. doi:10.1002/lt.21449
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Zhang C, Wu Q, et al. Application of immune repertoire sequencing in cancer immunotherapy. Int Immunopharmacol. 2019;74(105688):105688. doi:10.1016/j.intimp.2019.105688
   PubMedGoogle Scholar
• Six A, Mariotti-Ferrandiz ME, Chaara W, et al. The past, present, and future of immune repertoire biology - The rise of next-generation repertoire analysis. Front Immunol. 2013;4(413). doi:10.3389/fimmu.2013.00413
   Google Scholar
• Song L, Cohen D, Ouyang Z, et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat Methods. 2021;18(6):627–630. doi:10.1038/s41592-021-01142-2
   PubMed Web of Science ®Google Scholar
• Song L, Ouyang Z, Cohen D, et al. Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies. Cancer Immunol Res. 2022;10(7):788–799. doi:10.1158/2326-6066.Cir-21-0965
   PubMed Web of Science ®Google Scholar
• Chang YS, Hsu MH, Tu SJ, et al. Metatranscriptomic Analysis of Human Lung Metagenomes from Patients with Lung Cancer. Genes. 2021;12(9):1458. doi:10.3390/genes12091458
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi:10.1093/bioinformatics/btp616
   PubMed Web of Science ®Google Scholar
• Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3(4):493–500. doi:10.1001/jamaoncol.2016.5116
   PubMed Web of Science ®Google Scholar
• Liu Y, Al-Adra DP, Lan R, et al. RNA sequencing analysis of hepatocellular carcinoma identified oxidative phosphorylation as a major pathologic feature. Hepatol Commun. 2022;6(8):2170–2181. doi:10.1002/hep4.1945
   PubMed Web of Science ®Google Scholar
• Cui JH, Lin KR, Yuan SH, et al. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer. Front Immunol. 2018;9:2729. doi:10.3389/fimmu.2018.02729
   PubMed Web of Science ®Google Scholar
• Liu YY, Yang QF, Yang JS, et al. Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer. Int J Cancer. 2019;145(5):1423–1431. doi:10.1002/ijc.32145
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50. doi:10.1038/cr.2009.139
   PubMed Web of Science ®Google Scholar
• Usuelli V, Loretelli C, Seelam AJ, et al. Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection. Transplantation. 2022;106(3):500–509. doi:10.1097/tp.0000000000003834
   PubMed Web of Science ®Google Scholar
• Eggert T, Wolter K, Ji J, et al. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 2016;30(4):533–547. doi:10.1016/j.ccell.2016.09.003
   PubMed Web of Science ®Google Scholar
• Luo D, Zhang X, Li XK, et al. Identification of Key Functional Modules and Immunomodulatory Regulators of Hepatocellular Carcinoma. J Immunol Res. 2021;2021:1801873. doi:10.1155/2021/1801873
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• García-álvarez M, Berenguer J, Jiménez-Sousa MA, et al. Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: a cross-sectional study. Sci Rep. 2017;7(1):41516. doi:10.1038/srep41516
   PubMedGoogle Scholar
• Aljohani AI, Joseph C, Kurozumi S, et al. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res Treat. 2020;181(3):541–551. doi:10.1007/s10549-020-05646-x
   PubMed Web of Science ®Google Scholar
• Li C, Wang J, Zhang H, et al. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2014;5(18):8429–8441. doi:10.18632/oncotarget.2316
   PubMedGoogle Scholar
• Chen B, Jin S, Bai B, et al. Knockdown of interferon-stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin. Exp Ther Med. 2019;18(5):3751–3758. doi:10.3892/etm.2019.8028
   PubMed Web of Science ®Google Scholar
• Liu X, Lieberman J. Knocking ‘em Dead: pore-Forming Proteins in Immune Defense. Annu Rev Immunol. 2020;38(1):455–485. doi:10.1146/annurev-immunol-111319-023800
   PubMedGoogle Scholar
• Jo J, Bengsch B, Seigel B, et al. Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. J Hepatol. 2012;57(1):9–16. doi:10.1016/j.jhep.2012.02.030
   PubMed Web of Science ®Google Scholar
• Duan S, Gao J, Lou W, et al. Prognostic signature for hepatocellular carcinoma based on 4 pyroptosis-related genes. BMC Med Genomics. 2022;15(1):166. doi:10.1186/s12920-022-01322-9
   PubMed Web of Science ®Google Scholar
• Cowell LG. The Diagnostic, Prognostic, and Therapeutic Potential of Adaptive Immune Receptor Repertoire Profiling in Cancer. Cancer Res. 2020;80(4):643–654. doi:10.1158/0008-5472.Can-19-1457
   PubMed Web of Science ®Google Scholar
• Han Y, Liu X, Wang Y, et al. Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis. Oncoimmunology. 2015;4(8):e1021537. doi:10.1080/2162402x.2015.1021537
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang R, Deng J, et al. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(1):121–136. doi:10.1007/s00262-021-02967-8
   PubMed Web of Science ®Google Scholar